Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Patricia Guyot; Peter Taylor; Robin Christensen; Louisa Pericleous; Coralie Poncet; Maximilian Lebmeier; Pieter Drost; Gert Bergman

doi:10.1186/ar3537

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Patricia Guyot, Peter Taylor, Robin Christensen, Louisa Pericleous, Coralie Poncet, Maximilian Lebmeier, Pieter Drost, Gert Bergman

Parker Instituttet

40 Citationer (Scopus)

Abstract

The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (<2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR).

Originalsprog	Engelsk
Tidsskrift	Arthritis Research & Therapy
Vol/bind	13
Udgave nummer	6
Sider (fra-til)	R204
ISSN	1478-6354
DOI	https://doi.org/10.1186/ar3537
Status	Udgivet - 2011

Adgang til dokumentet

10.1186/ar3537

Andre filer og links

Link to publication in Scopus

Citationsformater

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. / Guyot, Patricia; Taylor, Peter; Christensen, Robin et al.
I: Arthritis Research & Therapy, Bind 13, Nr. 6, 2011, s. R204.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{189629efd8224c25abb91ea334a340f6,

title = "Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis",

abstract = "The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50\% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (<2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR).",

author = "Patricia Guyot and Peter Taylor and Robin Christensen and Louisa Pericleous and Coralie Poncet and Maximilian Lebmeier and Pieter Drost and Gert Bergman",

year = "2011",

doi = "10.1186/ar3537",

language = "English",

volume = "13",

pages = "R204",

journal = "Arthritis Research \& Therapy",

issn = "1478-6354",

publisher = "BioMed Central Ltd",

number = "6",

}

TY - JOUR

T1 - Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate

T2 - a network meta-analysis

AU - Guyot, Patricia

AU - Taylor, Peter

AU - Christensen, Robin

AU - Pericleous, Louisa

AU - Poncet, Coralie

AU - Lebmeier, Maximilian

AU - Drost, Pieter

AU - Bergman, Gert

PY - 2011

Y1 - 2011

N2 - The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (<2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR).

AB - The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (<2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR).

UR - https://www.scopus.com/pages/publications/83155163741

U2 - 10.1186/ar3537

DO - 10.1186/ar3537

M3 - Journal article

C2 - 22151924

SN - 1478-6354

VL - 13

SP - R204

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 6

ER -

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater